Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR wild-type (#RDB15488)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), wild type.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), wild type.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15488 pENTER-EGFR wild-type DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR wild-type was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15488).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15488_A7K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter, attL1, insert 5'
Sequence file: RDB15488_A7K8a.seq check
>D04925A1_A7K8_2_rrnBT1ter_F2_A04_01_ABI24.ab1
    1 AGTCAGATCT TCGACTGAGC CTTTCGTTTT ATTTGATGCC TGGCAGTTCC CTACTCTCGC
   61 GTTAACGCTA GCATGGATGT TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTCTTAA
  121 GCTCGGGCCC CAAATAATGA TTTTATTTTG ACTGATAGTG ACCTGTTCGT TGCAACAAAT
  181 TGATGAGCAA TGCTTTTTTA TAATGCCAAC TTTGTACAAA AAAGCAGGCT CCGCGGCCGC
  241 CCCCTTCACC ATGCGACCCT CCGGGACGGC CGGGGCAGCG CTCCTGGCGC TGCTGGCTGC
  301 GCTCTGCCCG GCGAGTCGGG CTCTGGAGGA AAAGAAAGTT TGCCAAGGCA CGAGTAACAA
  361 GCTCACGCAG TTGGGCACTT TTGAAGATCA TTTTCTCAGC CTCCAGAGGA TGTTCAATAA
  421 CTGTGAGGTG GTCCTTGGGA ATTTGGAAAT TACCTATGTG CAGAGGAATT ATGATCTTTC
  481 CTTCTTAAAG ACCATCCAGG AGGTGGCTGG TTATGTCCTC ATTGCCCTCA ACACAGTGGA
  541 GCGAATTCCT TTGGAAAACC TGCAGATCAT CAGAGGAAAT ATGTACTACG AAAATTCCTA
  601 TGCCTTAGCA GTCTTATCTA ACTATGATGC AAATAAAACC GGACTGAAGG AGCTGCCCAT
  661 GAGAAATTTA CAGGAAATCC TGCATGGCGC CGTGCGGTTC AGCAACAACC CTGCCCTGTG
  721 CAATGTGGAG AGCATCCAGT GGCGGGACAT AGTCAGCAGT GACTTTCTCA GCAACATGTC
  781 GATGGACTTC CAGAACCACC TGGGCAGCTG CCAAAAGTGT GATCCAAGCT GTCCCAATGG
  841 GAGCTGCTGG GGTGCAGGAG AGGAGAACTG CCAGAAACTG ACCAAAATCA TCTGTGCCCA
  901 GCAGTGCTCC GGGCGCTGCC GTGGCAAGTC CCCCCAGTGA CTGCTGCCAC AACCAGTGTG
  961 CTGCAGGCTG CACAGGCCCC CCGGGAGAGC GACTGCCCTG GGTCTGCCGC AAATTCCCGA
 1021 GACGAAAGCC ACGTGCAAGG ACACCTGCCC CCCCCACTCA TGCTCTACAA CCCCCACCAC
1081 GTACCAGATG TATGTGAAAC CCCGAGGGGC AAAATAACAA GCCTTTTTGG AATGC
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15488_A7K8b.seq check
>D04925A1_A7K8_2_pDONR_R_A08_02_ABI24.ab1
    1 GGCGGACGTC AGGGACGCTA TGACCATGTA ATACGACTCA CTATAGGGGA TATCAGCTGG
   61 ATGGCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC AAATTGATAA
  121 GCAATGCTTT CTTATAATGC CAACTTTGTA CAAGAAAGCT GGGTCGGCGC GCCCACCCTT
  181 TCATGCTCCA ATAAATTCAC TGCTTTGTGG CGCGACCCTT AGGTATTCTG CATTTTCAGC
  241 TGTGGAGCCC TTAAAGATGC CATTTGGCTT GGCTTCCTTG GGAAAGAAGT CCTGCTGGTA
  301 GTCAGGGTTG TCCAGGCTAA TTTGGTGGCT GCCTTTCTGG GCCCAGTGGG CAGGGCTGTC
  361 GAATGTGCTG TTGACACAGG TGGGCTGGAC AGTGTTGAGA TACTCGGGGT TGCCCACTGC
  421 AGTGCTGTGG GGGTCCTGGT AGTGTGGGTC TCTGCTGGGC GCGGGGTTCA GAGGCTGATT
  481 GTGATAGACA GGATTCTGCA CAGAGCCAGC GGGCCTTTTG GGAACGGACT GGTTTATGTA
  541 TTCAGGCACT GGGAGGAAGG TGTCGTCTAT GCTGTCCTCA GTCAAGGCGC CTGTGGGGTC
  601 TGAGCTGTAT CGCTGCAAGA AGCTGTCTTC CTTGATGGGA CAGCTTTGCA GCCCATTTCT
  661 ATCAATGCAA GCCACGGTGG AATTGTTGCT GGTTGCACTC AGAGAGCTCA GGAGGGGAGT
  721 CCGTGACGTG GAGGGGCTGC TGAAGAAGCC CTGCTGTGGG ATGAGGTACT CGTCGGCATC
  781 CACCACGTCG TCCATGTCTT CTTCATCCAT CAGGGCACGG TAGAAGTTGG AGTCTGTAGG
  841 ACTTGGCAAA TGCATTCTTT CATCCCCCCT GAATGACAAG GTAGCGCTGG GGGGTCTCGG
  901 GGCCATTTTG GAGAATTCGA TGATCAACTC ACGGGAACTT TGGGGCGACT ATCTGCGTCT
  961 ATCATCCAGC ACTTGACCAT GATCATGTAG ACATCGATGG TACATATGGG TGGCTGAGGG
 1021 AGGCGTTTCT CCCTTTTCTC CAGGATGGAG GAGATCTCGC TGGCAGGATC GGTCATATGG
1081 CCTTGGCATC CAAGGATCAA TCAACTTCTC A
//
Primer: EGFR-F5 (Pr0313)
Region: insert middle region
Sequence file: RDB15488_A7K8c.seq check
>D04925A1_A7K8_2_EGFR-F5_A09_03_ABI24.ab1
    1 AACAATAATC GTCCATCGCC ACTGGGATGG TGGGGGCCCT CCTCTTGCTG CTGGTGGTGG
   61 CCCTGGGGAT CGGCCTCTTC ATGCGAAGGC GCCACATCGT TCGGAAGCGC ACGCTGCGGA
  121 GGCTGCTGCA GGAGAGGGAG CTTGTGGAGC CTCTTACACC CAGTGGAGAA GCTCCCAACC
  181 AAGCTCTCTT GAGGATCTTG AAGGAAACTG AATTCAAAAA GATCAAAGTG CTGGGCTCCG
  241 GTGCGTTCGG CACGGTGTAT AAGGGACTCT GGATCCCAGA AGGTGAGAAA GTTAAAATTC
  301 CCGTCGCTAT CAAGGAATTA AGAGAAGCAA CATCTCCGAA AGCCAACAAG GAAATCCTCG
  361 ATGAAGCCTA CGTGATGGCC AGCGTGGACA ACCCCCACGT GTGCCGCCTG CTGGGCATCT
  421 GCCTCACCTC CACCGTGCAA CTCATCACGC AGCTCATGCC CTTCGGCTGC CTCCTGGACT
  481 ATGTCCGGGA ACACAAAGAC AATATTGGCT CCCAGTACCT GCTCAACTGG TGTGTGCAGA
  541 TCGCAAAGGG CATGAACTAC TTGGAGGACC GTCGCTTGGT GCACCGCGAC CTGGCAGCCA
  601 GGAACGTACT GGTGAAAACA CCGCAGCATG TCAAGATCAC AGATTTTGGG CTGGCCAAAC
  661 TGCTGGGTGC GGAAGAGAAA GAATACCATG CAGAAGGAGG CAAAGTGCCT ATCAAGTGGA
  721 TGGCATTGGA ATCAATTTTA CACAGAATCT ATACCCACCA GAGTGATGTC TGGAGCTACG
  781 GGGTGACCGT TTGGGAGTTG ATGACCTTTG GATCCAAGCC ATATGACGGA ATCCCTGCCA
  841 GCGAGATCTC CTCCATCCTG GAGAAAGGAG AACGCCTCCC TCAGCCACCC ATATGTACCA
  901 TCGATGTCTA CATGATCATG GTCAAGTGCT GGATGATAGA CGCAGATAGT CGCCCAAAGT
  961 TCCGTGAGTT GATCATCGAA ATTCTCCAAA ATGGGCCGAG ACCCCCAGCG CTACCCTTGT
 1021 CATTCAGGGG GATGAAAGAA TGCATTTGCC CAGTCCTACA GACTCCAACT CTAACGTGTC
1081 TGGATTGATG AAGAGGACAT TGGCACGAAA CCGT
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]